Full history for every metric is available with a Kvantra account
Creso Pharma Limited (CPH.AX)
Key financial summary
Financials in AUD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 0 | 1 | 4 | 2 | 6 | 9 | 4 |
| Operating profit | AUD m | -20 | -10 | |||||
| Net profit | AUD m | -15 | -17 | -17 | -38 | -32 | -33 | -17 |
| EPS reported | AUD | -0.02 | -0.12 | |||||
| Operating cashflow per share | AUD | -0.02 | -0.02 | |||||
| Capex per share | AUD | 0.00 | 0.00 | |||||
| FCF per share | AUD | -0.02 | -0.02 | |||||
| Free cash flow | AUD m | -31 | -14 | |||||
| Net debt | AUD m | 5 | 5 | |||||
| Book value equity | AUD m | 22 | 22 | |||||
| Book value per share | AUD | 0.02 | 0.16 | |||||
| Number of shares | m | 1,463.48 | 143.78 | |||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.31 | 1.04 | |||||
| P/S LTM | x | 3.37 | 6.37 | |||||
| P/FCF LTM | x | -0.94 | -1.71 | |||||
| EV/EBITDA LTM | x | -1.15 | -2.89 | |||||
| EV/Sales LTM | x | 3.98 | 7.83 | |||||
| Earnings Yield LTM | % | -112.00% | -248.89% | |||||
| FCF Yield | % | -106.53% | -58.47% | |||||
| Quality | ||||||||
| ROE | % | -147.04% | -130.99% | |||||
| ROIC | % | -67.55% | -67.55% | |||||
| Operating margin | % | -225.19% | -225.19% | |||||
| Gross margin | % | 3.30% | 3.30% | |||||
| FCF/Sales | % | -358.86% | -358.86% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +39.73% | +527.17% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -4.67 | -2.03 | |||||
| Net Debt/EBITDA | x | -0.18 | -0.18 | |||||
| EBIT/Net interest | x | -28.28 | -28.28 | |||||
| Net debt/market cap | % | 18.05% | 22.86% | |||||
| Net debt/Equity | x | 0.24 | 0.24 | |||||
| Gross debt/equity | x | 0.30 | 0.30 | |||||
Company overview
Creso Pharma Ltd. specializes in the development, registration, and commercialization of high-quality, pharmaceutical-grade cannabis and hemp-derived nutraceuticals. These health solutions are designed for both human and animal wellness, distributed across Europe, the Middle East, North America, and the Asia Pacific. The company also undertakes the creation and sale of therapeutic products, in addition to cultivating, processing, and supplying cannabis products to retail markets. Among its diverse product line are "anibidiol," a complementary feed for companion animals; "cannaQIX," a nutraceutical containing hemp oil extract, vitamins, and zinc, formulated to reduce stress and support psychological and nervous system functions; and topical skincare items like "cannaDOL," a CBD-based gel featuring a blend of cooling and warming essential oils. Creso Pharma Limited was founded in 2015 and operates from its headquarters in Nedlands, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Creso Pharma Limited (CPH.AX)
Creso Pharma Ltd. specializes in the development, registration, and commercialization of high-quality, pharmaceutical-grade cannabis and hemp-derived nutraceuticals. These health solutions are designed for both human and animal wellness, distributed across Europe, the Middle East, North America, and the Asia Pacific. The company also undertakes the creation and sale of therapeutic products, in addition to cultivating, processing, and supplying cannabis products to retail markets. Among its diverse product line are "anibidiol," a complementary feed for companion animals; "cannaQIX," a nutraceutical containing hemp oil extract, vitamins, and zinc, formulated to reduce stress and support psychological and nervous system functions; and topical skincare items like "cannaDOL," a CBD-based gel featuring a blend of cooling and warming essential oils. Creso Pharma Limited was founded in 2015 and operates from its headquarters in Nedlands, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free